BioLineRx has completed subject enrolment in the Phase I/IIa trial of its intratumoural cancer vaccine candidate, AGI-134, to treat unresectable metastatic solid tumour patients.

A synthetic alpha-Gal glycolipid, AGI-134 is intended to label cancer cells with alpha-Gal through intra-tumoral administration. It thereby acts on the already existing anti-alpha-Gal (anti-Gal) antibodies in the body and redirects them to treated tumours. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The multicentre, open-label trial recruited 38 subjects in the UK, Spain, and Israel. The company expects data on the safety and proof of mechanism of AGI-134 in the first half of this year.

The study consists of two parts. The completed Part 1 dose-escalation study enrolled five subjects to detect the maximum tolerated dose as well as the recommended dose for part 2 of the trial.

A dose-expansion study, Part 2 enrolled 33 subjects to assess the tolerability and safety of AGI-134 at the recommended dose.

It also intends to establish the mechanism of action of AGI-134 using several biomarkers.

BioLineRx CEO Philip Serlin said: “AGI-134, our second clinical-stage oncology asset, has a unique mode of action, applicable to all injectable tumour types.

“This clinical study aims to confirm the proposed mechanism of action and safety profile of AGI-134 in humans, based on which we also plan to explore potential combinations as part of its future clinical development programme.”

AGI-134 treatment offered regression of established primary tumours as well as secondary tumour (metastases) development suppression in a mouse melanoma model.

In addition, synergy was observed in further pre-clinical studies on combining with an anti-programmed cell death protein 1 (PD1) immune checkpoint inhibitor, thereby providing the potential to expand the use of such immunotherapies and boost the response rate and extend in various types of cancer.

The company is set to commence Phase Ib trial of Motixafortide in patients with acute respiratory distress syndrome (ARDS) secondary to Covid-19 and other respiratory viral infections.

BioLineRx obtained AGI-134 through takeover of Agalimmune.